Estrogen Receptor-positive Breast Cancer
41
2
7
21
Key Insights
Highlights
Success Rate
72% trial completion
Published Results
21 trials with published results (51%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
19.5%
8 terminated out of 41 trials
72.4%
-14.1% vs benchmark
2%
1 trials in Phase 3/4
100%
21 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (41)
A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Personalised Disease Monitoring in Metastatic Breast Cancer
Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Biology Guided Therapy for Breast Cancer for ER Positive
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Pre-operative Immunotherapy Combination Strategies in Breast Cancer
Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer
Patterns of Prescribing and Monitoring of Palbociclib
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
Phase II Study of Everolimus Beyond Progression
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer